These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Effect of celecoxib on enhancing the chemotherapic sensitivity of hydroxyurea to K562 cells and its mechanism].
    Author: Liu DS, Zhang GS.
    Journal: Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2004 Oct; 29(5):495-9. PubMed ID: 16137030.
    Abstract:
    OBJECTIVE: To determine whether celecoxib can enhance the anti-proliferative effect of hydroxyurea on K562 cells and to reveal its molecular mechanism. METHODS: K562 cells were treated with low dose celecoxib (40 micromol/L) or hydroxyurea (10 mmol/L) and celecoxib (40 micromol/L) combined with hydroxyurea (10 mmol/L) for 36 h. The effects of the drugs on K562 cell growth inhibitation, apoptosis inducement and its molecular mechanism were analyzed by MTT assay, DNA fragment analysis, Western blotting, and RT-PCR. RESULTS: The treatment of celecoxib (40 micromol/L) combined with hydroxyurea (10 mmol/L) could significantly inhibit the K562 cell viability and induce the K562 cell apoptosis than those treatments of celecoxib or hydroxyurea alone. The combination of celecoxib and hydroxyurea could evidently inhibit the expression of COX-2 protein or COX-2 mRNA of K562 cells. CONCLUSION: Celecoxib can enhance the anti-proliferative effect of hydroxyurea on K562 cells, which is associated with the down-regulation of both COX-2 protein and COX-2 mRNA on K562 cells.
    [Abstract] [Full Text] [Related] [New Search]